Last Updated: August 9, 2026

Drug Price Trends for CIPRO HC

✉ Email this page to a colleague

« Back to Dashboard

Drug Price Trends for CIPRO HC

Average Pharmacy Cost for CIPRO HC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.87532	ML	2026-07-22
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.86626	ML	2026-06-17
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.86528	ML	2026-05-20
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.87060	ML	2026-04-22
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.86309	ML	2026-03-18
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.84881	ML	2026-02-18
CIPRO HC OTIC SUSPENSION	66758-0087-70	34.85095	ML	2026-01-21
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Best Wholesale Price for CIPRO HC

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Subscribe to access the full database, or Start Trial

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
CIPRO HC,SUSP,OTIC	Sandoz, Inc.	00078-0855-26	10ML	238.94	23.89400	ML	2023-09-29 - 2028-08-14	FSS
CIPRO HC,SUSP,OTIC	Sandoz, Inc.	00078-0855-26	10ML	240.12	24.01200	ML	2024-01-01 - 2028-08-14	FSS
>Drug Name	>Vendor	>NDC	>Count	>Price ($)	>Price/Unit ($)	>Unit	>Dates	>Price Type

CIPRO HC (ciprofloxacin + hydrocortisone) Market Analysis and Price Projections: U.S. Pricing, Exclusivity/Generic Risk, and Revenue Outlook

Last updated: July 10, 2026

Executive summary: CIPRO HC (ciprofloxacin 0.2%/hydrocortisone acetate 1%) is a niche U.S. branded ophthalmic/otic anti-infective plus steroid product line with limited unit scale versus blockbuster ophthalmics. Competitive pressure is driven by generic ophthalmic antibiotic/steroid combinations and by the shelf-life economics typical of low-to-mid single digit millions in annual prescriptions. Near-term pricing power is constrained by generic substitutions and payer preference. Downside risk is highest where Orange Book-listed exclusivity has already lapsed or where multiple ANDA versions exist. Upside is limited to reimbursement stability and to brand resilience in accounts that retain a branded preference through formulary inertia.

No complete patent estate, Orange Book status, FDA approval/labeling history, or current U.S. NDC-level pricing/volume basis was provided in the prompt. Without those inputs, this analysis cannot be completed to the standard required for defensible price projections and market sizing tied to launch/expiration dates, Paragraph IV timelines, or current competitive supply.

More… ↓

⤷ Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.